<i>EGFR</i>Exon 19 Insertions: Do Patients Respond to Tyrosine Kinase Inhibitor Treatment?
Patients with EGFR insertions in exon 19 have demonstrated sensitivity to treatment with EGFR TKIs, suggesting that patients carrying these mutations should be treated with these inhibitors.
Authors
- Ludmila Carmen Omer (ORCID: https://orcid.org/0009-0006-8145-9535)
- Angela Zupa
- Giovanni Calice (ORCID: https://orcid.org/0000-0002-2545-1401)
- Giulia Vita (ORCID: https://orcid.org/0000-0002-1060-0160)
- Giuseppina Improta (ORCID: https://orcid.org/0000-0001-5175-5903)
- Alfredo Tartarone (ORCID: https://orcid.org/0000-0002-0859-7847)
Institutions
- Centro di Riferimento Oncologico della Basilicata (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Anticancer Research
- Published
- 2024-12-30
- DOI
- https://doi.org/10.21873/anticanres.17421
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00